Innovative Funding Initiatives for Lung Cancer Research
Introducing a new funding mechanism, the Lung Cancer Research Foundation (LCRF) has initiated the groundbreaking 2025 LCRF Team Science Award aimed at advancing therapies for EGFR mutant lung cancers. With a total of $1.5 million over three years, this award emphasizes collaborative efforts among scientific teams to generate innovative breakthroughs. The Request for Proposals (RFP) is now officially open for submissions.
Focus on EGFR Mutant Lung Cancer
Lung cancer represents a significant health concern globally, responsible for approximately 124,730 annual deaths in the United States alone. Intensive efforts over the past decade, including accelerated clinical trials and FDA approvals for targeted therapies, have made strides in treating non-small cell lung carcinoma (NSCLC). This progress owes much to advancements in molecular profiling that helps identify oncogenic drivers leading to specific treatment pathways.
Among these drivers, epidermal growth factor receptor (EGFR) mutations have been pivotal. They marked the successful targeting of oncogenic drivers through tyrosine kinase inhibitors (TKIs). Additional discoveries of other oncogenic driver alterations such as EML4-ALK, BRAF, RET, KRAS G12C, HER2, MET, NTRK, ROS1, and NRG1 have emerged, enhancing therapeutic options available to patients. Several FDA-approved TKIs, including gefitinib, erlotinib, afatinib, dacomitinib, and lastly, osimertinib, have made a significant impact in treating EGFR mutated (EGFRmut+) NSCLC.
The Need for Innovative Treatment Options
Despite considerable advancements, existing treatments for EGFRmut+ lung cancers are not curative, and resistance typically presents over time. Oftentimes, medical professionals resort to repeat biopsies, aiming to identify the sources of resistance, which may enable evaluation for alternative targeted therapies. Chemotherapy usually becomes a necessary component of treatment as well. While immunotherapy, including PD-1/PD-L1 inhibitors, has transformed the treatment landscape for various lung cancer types, it has yet to show efficacy against many oncogene-driven lung cancers.
In light of these challenges, there is an pressing need for innovative therapeutic approaches that seek to not only extend treatment efficacy but also offer curative potential for patients battling EGFRmut+ NSCLC. The LCRF Team Science Award aims to direct funding towards research initiatives that focus on developing novel therapies.
A Voice for Patients
Benay Taub, a lung cancer survivor, emphasizes the importance of ongoing research: "There has been so much scientific discovery in EGFR mutant lung cancer. Patients are living longer due to advances in targeted treatments. However, as resistance develops, more treatment options are essential. The goal of this award is to support dedicated researchers pursuing improved outcomes for lung cancer patients and striving towards a cure."
Commitment to Scientific Discovery
Dr. Antoinette Wozniak, Chief Scientific Officer for LCRF, echoes this sentiment, stating, "EGFR discoveries initiated the oncogene-driven treatment paradigm. Significant progress has been made, yet much more remains to be uncovered. Our clear commitment is to fund research that pushes scientific boundaries towards finding a cure for lung cancer." Furthermore, David Carbone, MD, PhD, Director of the Translational Therapeutics Program at The Ohio State University Wexner Medical Center and member of LCRF’s Scientific Advisory Board, notes, "Taking a team approach to combat resistance in EGFR mutant lung cancer promises to accelerate discovery."
Funding Application Process
The Team Science Award is made possible thanks to a generous private donation from Benay and Steven Taub, who passionately believe in the collaborative nature of scientific discovery. Interested parties can submit Letters of Intent until the specified deadline. Selected projects will then advance to full proposals, subject to a thorough review process conducted by LCRF’s Scientific Advisory Board. Detailed application guidelines, eligibility information, and necessary deadlines are available on the LCRF website.
Frequently Asked Questions
What is the purpose of the 2025 LCRF Team Science Award?
The award aims to fund innovative projects focused on curing EGFR mutated lung cancers through collaborative scientific research.
How much funding is provided through the LCRF Team Science Award?
The award provides up to $1.5 million over three years to support selected research projects.
Who can apply for the LCRF Team Science Award?
Scientific teams working on innovative approaches to treat EGFR mutated lung cancers can submit proposals as part of the application process.
What is required for the submission process?
Applicants must submit Letters of Intent by the deadline, and successful submissions will progress to a full proposal stage with specific requirements.
How has the LCRF contributed to lung cancer research?
The Lung Cancer Research Foundation has funded 429 research grants totaling nearly $48 million, focusing on extending survival and improving the quality of life for lung cancer patients.
